Bacteria Patents (Class 530/825)
-
Patent number: 4966837Abstract: Recombinant DNA transfer vectors containing DNA inserts which are complementary to either the human LDL receptor gene, or its mRNA transcript, are disclosed. Also disclosed are methods which utilize these genetic probes for diagnosing Familial Hypercholesterolemia (FH) in a suspected individual. A case study of numerous such individual are disclosed wherein the genetic deletion mutation is detailed with great precision through the practice of this invention.Type: GrantFiled: October 30, 1986Date of Patent: October 30, 1990Assignee: Board of Regents, The University of Texas SystemInventors: Michael S. Brown, Joseph L. Goldstein, David W. Russell
-
Patent number: 4966765Abstract: The subject invention concerns a novel and useful insecticide with activity against insect pests of the order Coleoptera. Pests in the order Coleoptera do heavy damage to crops, e.g., corn. The insecticide of the subject invention is a novel B. thuringiensis microbe referred to as B.t. PS86B1, or mutants thereof. The spores or crystals of this microbe are useful to control coleopteran pests in various environments.Type: GrantFiled: February 23, 1988Date of Patent: October 30, 1990Assignee: Mycogen CorporationInventors: Jewel Payne, Michelle Burrascano, George G. Soares
-
Patent number: 4965192Abstract: An interspecific antigen of Mycobacteria consists essentially of a mixture in substantially immunochemically pure form of a protein having a molecular weight of at least about 4.times.10.sup.6 Daltons and polysaccharide having a molecular weight of at least about 1.times.10.sup.6 Daltons, and has when subjected to cross-electrophoresis an immunoelectrophoretic precipitation pattern corresponding to A60-antigen of Mycobacteria bovis strain BCG. This antigen is effective for detecting the prior exposure of a subject to Mycobacterial infections by a cutaneous test.Type: GrantFiled: April 29, 1988Date of Patent: October 23, 1990Assignee: Anda BiologicalsInventor: Roland F. Maes
-
Patent number: 4959455Abstract: A novel family of primate IL-3 polypeptides is provided via recombinant techniques.Type: GrantFiled: March 4, 1987Date of Patent: September 25, 1990Assignee: Genetics Institute, Inc.Inventors: Steven C. Clark, Agnes B. Ciarletta, Yu-Chung Yang
-
Patent number: 4957739Abstract: Novel compositions are disclosed for use in the treatment or diagnosis of bovine pasteurellosis, commonly referred to as Shipping Fever. Cell-free Pasteurella haemolytica supernatants are employed to provide individual antigen compositions, identified through reaction with sera from naturally-infected or convalescent cattle. In particular, at least seven individual P. hameolytica antigen groups were recognized in cell-free culture supernatants. Purified P. haemolytica supernatant, formulated in a suitable pharmaceutical vaccine composition is shown to elicit a specific immune response, in both cows and rabbits, directed against the individual immunoreactive P. haemolytica polypeptides identified. Also disclosed are novel recombinant cells, plasmids and bacteriophage which include transcriptionally active P. haemolytica antigen genes. Recombinant clones are similarly selected to be reactive with naturally-infected antisera.Type: GrantFiled: August 13, 1987Date of Patent: September 18, 1990Assignee: Board of Regents, The University of Texas SystemInventors: Peter Berget, Michael Engler, Sarah Highlander, George Weinstock
-
Patent number: 4958007Abstract: A method is provided for extracting human interleukin-4 (IL-4) from IL-4 expressing bacterial cells. The method comprises treating the bacterial cells with a deactivating agent, disrupting the cell membrane and recovering the IL-4.Type: GrantFiled: May 17, 1988Date of Patent: September 18, 1990Assignee: Schering-Plough Corp.Inventors: Yair Alroy, Paul Leibowitz
-
Patent number: 4950589Abstract: Antigens characteristic of all species of Listeria except L. denitrificans comprising proteins found in Listeria heat extracts, the major antigen having a molecular weight of from about 30 to about 38KD and comprising three immunogenically different epitopes and others comprising proteins having a molecular weight range of approximately 17KD to the major antigen and comprising an epitope immunoreactive with antibodies that are also reactive with one of the three epitopes on the 30 to about 38KD protein. The invention also comprises mouse monoclonal antibodies specifically reactive with the identified epitopes on these antigens.Type: GrantFiled: August 10, 1987Date of Patent: August 21, 1990Assignee: Akzo N.V.Inventors: Bryan T. Butman, Jerome A. Mattingly
-
Patent number: 4950740Abstract: Recombinant diphtheria toxin A fragment muteins which are enzymatically inactive but immunologically crossreactive with diphtheria toxin are disclosed. Intermediates and methods for preparing such proteins using recombinant techniques are also described.Type: GrantFiled: March 7, 1988Date of Patent: August 21, 1990Assignee: Cetus CorporationInventors: Lawrence Greenfield, Anne W. Emerick, Walter J. Laird
-
Patent number: 4948874Abstract: A process is disclosed for recovering a cell wall protein, particularly a Fc-receptor, from streptococcal bacteria. In the process, streptococcal bacteria are treated with at least one proteolytic enzyme to solubilize the cell wall protein. A process is also disclosed for recovering Fc-receptor type III (protein G) having selective IgG-binding capability (i.e., no albumin-binding capability) from streptococcal bacteria by pretreating these bacteria with enzymes prior to said enzymatic solubilization.Type: GrantFiled: February 15, 1989Date of Patent: August 14, 1990Assignee: Pharmacia ABInventors: Goran Kronvall, Lars Bjorck
-
Patent number: 4946677Abstract: Preparations active against Pseudomonas aeruginosa Infections, namely vaccines for active immunization as well as preparations containing antibodies and destined for passive protection; as well as methods for the production thereof.The vaccines contain protective flagellar (H) antigens of the serotype a and b, which consist of monomeric components, each monomeric component is composed of certain amino acids having a certain N-terminal amino acid sequence and has a certain molecular weight. The vaccines are made from purified flagellar (H) antigen solutions. The immunoglobulin-G-containing preparations contain flagellar (H) antibodies obtained from the blood plasma of human donors or mammals immunized with protective flagellar (H) antigens. They can be purified by methods of affinity chromatography.Type: GrantFiled: June 17, 1987Date of Patent: August 7, 1990Assignee: Immuno Aktiengesellschaft fur Chemisch-Medizinische ProdukteInventors: Friedrich Dorner, Johann Eibl
-
Patent number: 4945157Abstract: Protein G from wild-type group G or group C streptococci is obtained by an extracting process using cyanogen bromide. The process gives yields ranging up to 60-fold better than the best prior art process known.Type: GrantFiled: May 27, 1988Date of Patent: July 31, 1990Assignee: University of FloridaInventors: Michael D. P. Boyle, Ervin Faulmann
-
Patent number: 4945057Abstract: Murine hybridomas are disclosed which were constructed by fusing spleen cells from BALB/c mice immunized with soluble crystal protein from Bacillus thuringiensis subsp. israelensis (B.t.i.) to the murine myeloma cell line SP2/0-AG14. An ELISA (enzyme-linked immunosorbent assay) method for detection of antibodies specific for crystal protein of B.t.i. was modified to produce 100- to 1,000-fold increased sensitivity and was used to identify hybridomas secreting monoclonal antibody specific for the B.t.i. crystal protein. Analysis of the hybridoma culture supernatant fluid indicated production of monoclonal IgG3 antibodies, specific for the 68,000 dalton protein presumed to be the insecticidal delta-endotoxin of B.t.i.Type: GrantFiled: May 18, 1987Date of Patent: July 31, 1990Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Kevin B. Temeyer, Maurice Haufler, John H. Pruett
-
Patent number: 4939094Abstract: The present invention provides a hybrid antigen polypeptide having both antigenicity of the ATLA encoded by gag gene and that of the ATLA encoded by env gene. The hybrid antigen can be produced in a large amount and it is applicable to serum diagnosis of patients infected with antigen polypeptides such as ATLV.Type: GrantFiled: August 15, 1986Date of Patent: July 3, 1990Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Tetsuro Kuga, Susumu Sekine, Seiga Itoh
-
Patent number: 4933435Abstract: Immunoglobulins are purified by adsorption upon and adsorbent therefor using a buffer having a pH value of about pH 6 to pH 10 and containing at least one polycarboxylic acid in a concentration of about 0.5 M to about 0.9 M.Type: GrantFiled: April 5, 1989Date of Patent: June 12, 1990Assignee: Bioprobe InternationalInventor: That T. Ngo
-
Patent number: 4931543Abstract: A process for recovering substantially pure rIL-2 from transformed microorganisms in which the cells are disrupted, impure insoluble rIL-2 is separated from the bulk of the cellular components, the separated impure rIL-2 is solubilized and partially purified in a reduced form, the solubilized rIL-2 is oxidized, the oxidized rIL-2 is purified to clinically acceptable levels, and the oxidized, purified IL-2 is denatured by placing it into a solution of a chaotropic agent, solids are removed from the solution and rIL-2 is renatured from the solution.Type: GrantFiled: March 25, 1988Date of Patent: June 5, 1990Assignee: Cetus CorporationInventors: Robert Halenbeck, Flint Smith, Michael Kunitani
-
Patent number: 4929700Abstract: A process for recovering dimeric, biologically active CSF-1 from bacterially expressed recombinant CSF1 genes is described. The process comprises recovery of the solubilized monomeric form, followed by dimerization under refolding conditions and further purification of the dimer. Heterodimers may also be produced by this process.Type: GrantFiled: April 8, 1988Date of Patent: May 29, 1990Assignee: Cetus CorporationInventors: Robert Halenbeck, Kriston Koths, Cynthia Cowgill, Walter J. Laird
-
Patent number: 4925784Abstract: Methods and compositions are provided for the cloning and expression of plasmids bearing genes encoding a novel protein derived from HTLV-III. This protein, which is called the gag/env protein and which contains antigenic determinants from both the core and envelope proteins of HTLV-III, can be purified to homogeneity and used as the basis for diagnostic tests to detect the presence of antibodies against viruses associated with AIDS or the viruses themselves in human sera and other biological fluids. The gag/env protein may also be formulated for use as a vaccine for protection against AIDS through prophylactic immunization.Type: GrantFiled: April 4, 1986Date of Patent: May 15, 1990Assignee: Hoffmann-La Roche Inc.Inventors: Robert M. Crowl, Daru Young
-
Patent number: 4918163Abstract: The present invention provides novel hybridoma cell lines which produce monoclonal antibodies (MoAbs) that bind epitopes found on lipopolysaccharide most commonly associated with the endotoxin core of gram negative bacteria and exhibit broad cross-reactivity with gram negative bacteria of different genera and effectively neutralize endotoxin. At least one of the MoAbs disclosed (XMMEN-J5D) binds an epitope also found on gram positive bacteria. The hybridomas are produced by fusing an immortal cell, a cell having the ability to replicate indefinitely in myeloma cell culture, and an effector immune cell following immunization of the immune cell host with a preparation of a gram negative bacteria. While several individual hybridoma cell lines producing monoclonal antibodies to lipopolysaccharide are described, the present invention adds to the state of the art an entire family of hybridoma producing monoclonal antibodies to lipopolysaccharide-associated epitopes.Type: GrantFiled: April 24, 1986Date of Patent: April 17, 1990Assignee: Pfizer Inc.Inventor: Lowell S. Young
-
Patent number: 4915942Abstract: Synthetic peptides containing non-repeating epitopes of circumsporozoite derived protein antigen and which are substantially shorter in length than the intact antigen are disclosed. The peptides when administered to a host raise antibodies in that host that will bind to the circumsporozoite antigen on the parasite. Vaccines based upon these peptides, as well as means of raising antibodies to circumsporozoite antigens using the synthetic peptides are also disclosed.Type: GrantFiled: October 26, 1987Date of Patent: April 10, 1990Assignee: New York UniversityInventors: Ulises Vergara, Andres Ruiz, Arturo Ferreira, Ruth S. Nussenzweig, Victor N. Nussenzweig
-
Patent number: 4912200Abstract: A method of extracting granulocyte macrophage colony stimulating factor (GM-CSF) from GM-CSF-expressing bacterial cells comprising treating a suspension of GM-CSF-containing bacterial cells with an acid and an enhancing agent, removing substantially all of the suspension liquid from the cells, preparing a second suspension of the acidified cells, neutralizing said second suspension, and separating the GM-CSF containing liquid from the suspended cells.Type: GrantFiled: May 11, 1987Date of Patent: March 27, 1990Assignee: Schering CorporationInventors: Paul Leibowitz, Yair Alroy
-
Patent number: 4902673Abstract: A bidifobacteria growth promoter contained in soybeans is extracted from defatted soybeans with an aqueous solution of alcohol.Type: GrantFiled: November 9, 1988Date of Patent: February 20, 1990Assignee: The Calpis Food Industry Co., Ltd.Inventors: Kunihiko Hayakawa, Teruhisa Masai, Yasuyuki Yoshida, Takanobu Shibuta, Hiroshi Miyazaki
-
Patent number: 4900660Abstract: Proteinaceous, antigenic factor derived from a group C Streptococcus which is receptor for the Fc region of IgG, a method for its preparation and immunoassay and antigen detection methods employing the receptor.Type: GrantFiled: November 25, 1985Date of Patent: February 13, 1990Assignee: University of FloridaInventors: Michael D. P. Boyle, Kathleen J. Reis, Elia M. Ayoub
-
Patent number: 4894443Abstract: A novel class of polypeptides of the general formula (F-(Pro).sub.n).sub.m F, wherein F represents a flexible amino acid sequence wherein each amino acid is individually selected from the group consisting of serine, glycine, and threonine, and n is an integer from 4-8 inclusive and m is an integer from 1-4 inclusive, is disclosed. Thses polypeptides are useful in the construction of conjugates between antibodies and peptide toxins. The preparation of such conjugate toxins by linking antibodies to toxin/spacer composites prepared by recombinant techniques is also disclosed.Type: GrantFiled: September 7, 1984Date of Patent: January 16, 1990Assignee: Cetus CorporationInventors: Lawrence I. Greenfield, Donald A. Kaplan, Danute E. Nitecki
-
Patent number: 4894328Abstract: A component for the rapid detection of anti-Treponema pallidum antibodies adapted for use as a selective foundation material in standard immunoassays is provided. The component comprises a quantity of fibronectin insolubilized to a solid matrix. The fibronectin component provides a foundation material for the selective binding of antigenic outer membrane proteins extracted from Treponema pallidum. Incorporation of the insolubilized fibronectin component bound to the antigenic outer membrane proteins extracted from Treponema pallidum into a standard immunoassay test pack provides an immunological assay for the presence of respective complementary anti-Treponema pallidum antibody in a biological sample.Type: GrantFiled: May 4, 1987Date of Patent: January 16, 1990Assignee: Board of Regents, The University of Texas SystemInventors: John F. Alderete, Joel B. Baseman
-
Patent number: 4894439Abstract: A process is disclosed for the purification of recombinantly produced biologically active proteins in which a solution containing a mixture of materials, including the biologically active protein, is passed through a continuous porous hydrophobic membrane, and the fraction enriched in the biologically active protein is recovered. Hydrophobic proteins such as TNF and recombinant ricin toxin A chain may be purified according to the process. Conditions for enhanced recovery of purified TNF using the process are disclosed. A highly purified TNF comprising 95% or greater TNF as determined by SDS-PAGE analysis, with an endotoxin content of less than 0.1 ng/mg TNF which is substantially free of pyrogens by the USP rabbit pyrogen test at a dosage range of 1.0 to 2.4.times.10.sup.5 U/kg, is obtained.Type: GrantFiled: May 22, 1986Date of Patent: January 16, 1990Assignee: Cetus CorporationInventors: Glenn Dorin, Wolfgang H. Hanisch, James W. Thomson, Sidney N. Wolfe, Leo S. Lin
-
Patent number: 4885359Abstract: Improved method for the purification of LPF-HA (Leucocytosis promoting far hemagglutinin) on industrial scale which comprises contacting a LPF-HA-containing solution from culture media of Bordetella pertussis with a cellulose sulfate gel, a crosslinked polysaccharide sulfate gel, or a polysaccharide gel chemically bound with dextran sulfate, thereby adsorbing LPF-HA on the gel, and then eluting LPF-HA from the gel. Said method can give a highly purified LPF-HA which does not contain any other proteins, lipid, saccharides, etc. and further undesirable endotoxin, and hence can be used for producing various reagents, medicines and pertussis vaccine.Type: GrantFiled: November 16, 1987Date of Patent: December 5, 1989Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteInventors: Akihiro Ginnaga, Tsukasa Nishihara, Tetsuo Kawahara, Sadao Susumi, Hiroshi Mizokami, Mitsuo Sakoh
-
Patent number: 4883754Abstract: A type II, Proteinaceous, antigenic factor derived from a Group A streptococcus which is a receptior for the Fc region of human Ig G3 and which exhibits a major diffuse protein band on polyacrylamide gel electrophoresis and which has a molecular weight of about 38,000 daltons.Type: GrantFiled: March 6, 1986Date of Patent: November 28, 1989Assignee: University of Florida Research FoundationInventors: Michael D. P. Boyle, Michele Yarnall
-
Patent number: 4882425Abstract: Described is composition of matter and methods useful for the indentification of blood group antigens. Additionally a kit which can be used to identify and quantify a large number of blood group antigens is disclosed. The composition of matter and the methods can be used to identify antigens on red blood cells, as well as, on tissue samples.Type: GrantFiled: July 9, 1987Date of Patent: November 21, 1989Assignee: Baylor College of MedicineInventors: Richard A. Hull, Sheila I. Hull, Bogdan Nowicki
-
Patent number: 4876194Abstract: This invention relates to a new protein L and subfragments thereof with binding activity for all classes of immunoglobulins from different species, a process for preparing the same, a reagent kit, a pharmaceutical composition and strain 312 of P. magnus. The process for preparing the protein and subfragments thereof is characterized in that the microorganism P. magnus 312 is treated with proteolytic enzymes or mutanolysin.Type: GrantFiled: July 22, 1986Date of Patent: October 24, 1989Assignee: Hightech Receptor ABInventors: Lars Bjorck, Mats Erntell, Erling Myhre
-
Patent number: 4867976Abstract: A method for treatment of acquired immuno-deficiency syndrome (AIDS) which comprises administering a therapeutically effective amount of liposomes containing a toxin which specifically inhibits the protein synthesis in cells to a patient with AIDS.Type: GrantFiled: July 2, 1987Date of Patent: September 19, 1989Assignee: Sumitomo Chemical Company, LimitedInventors: Shigeharu Ueda, Kazuyoshi Ikuta, Shiro Kato, Tsuyoshi Uchida
-
Patent number: 4866034Abstract: A method is provided for producing an effective adjuvant response or stimulating the immune response of a warm blooded animal which comprises administering to said warm blooded animal an effective amount of a composition comprising refined detoxified endotoxin in combination with a pharmaceutically acceptable carrier.Type: GrantFiled: May 8, 1985Date of Patent: September 12, 1989Assignee: Ribi Immunochem Research Inc.Inventor: Edgar E. Ribi
-
Patent number: 4863852Abstract: A method is provided for detecting the presence of C. difficile toxin A. Stool or other appropriate specimen is contacted with a reagent containing an available non-reducing galactose-alpha-1-3-galactosyl structure, which is a specific receptor for toxin A. The reagent may be intact cells, cell membranes, membrane fractions containing the toxin A receptor structure, glycoconjugates, as well as the purified toxin A receptor per se. Binding of toxin A is determined by conventional assay techniques. The method may also be used to isolate and purify toxin A. Conversely, immobilized toxin A is used to detect, isolate, or purify biological materials of interest containing the receptor structure.Type: GrantFiled: February 11, 1986Date of Patent: September 5, 1989Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Tracy D. Wilkins, Howard C. Krivan
-
Patent number: 4861707Abstract: A recombinant peptide displaying the antigenicity of Human Immunodeficiency Virus (HIV) viral antigens is disclosed. The peptide comprises an antigenic segment having about 150 to about 400 amino acids corresponding to at least about 30 amino acids of the C-terminal of the gp120 domain and at least about 120 amino acids of the N-terminal of the gp41 domain.Type: GrantFiled: February 2, 1987Date of Patent: August 29, 1989Assignee: E. I. Du Pont de Nemours and CompanyInventors: Lucinda A. Ivanoff, Steven R. Petteway
-
Patent number: 4861754Abstract: It has been found that bacteriocins are able to kill virally-infected mammalian cells, including virally infected white blood cells. Accordingly, viral infections can be detected and ultimately treated using the bacteriocins and the methods described herein. The invention is particularly suited to detection and treatment of AIDS infection and infectious mononucleosis infection.Type: GrantFiled: May 26, 1987Date of Patent: August 29, 1989Inventor: Hannah Farkas-Himsley
-
Patent number: 4851333Abstract: Method and compositions including monoclonal antibodies to a serogroup-common antigen are provided for the detection and diagnosis of Legionella pneumophila. The monoclonal antibodies recognize a proteinaceous antigen of molecular weight 28,000-29,000 Daltons which is detected in at least serogroups 1 through 8 of Legionella pneumophila and is not detected in other common respiratory pathogens.Type: GrantFiled: February 24, 1984Date of Patent: July 25, 1989Assignee: Genetic Systems CorporationInventors: Lynn C. Goldstein, Larry H. Gosting
-
Patent number: 4849341Abstract: The present invention relates to (1) an enzyme-linked immunosorbent assay (ELISA) for detection in milk of antibodies of any isotype which are specific for Staphylococcus aureus proteins in molecular weights ranging from 18,000 to 26,000 daltons, (2) a process for production and purification of said proteins, (3) a method of performing said ELISA utilizing said proteins and (4) use of said ELISA for detection of intramammary infection by S. aureus.Type: GrantFiled: December 2, 1986Date of Patent: July 18, 1989Assignee: ProScience CorporationInventors: D. Scott Adams, Irwin C. McGuire, Jr.
-
Patent number: 4845036Abstract: A method for dissociating the B oligomer of pertussis toxin comprising incubating pertussis toxin in an aqueous solution of urea, sodium phosphate buffer, and a nucleotide selected from the group consisting of ATP and ADP, and optional zwitterionic detergent; applying the incubated solution to a CM-Sepharose column; and eluting the B oligomer from the column with potassium phosphate buffer containing urea.Type: GrantFiled: February 3, 1987Date of Patent: July 4, 1989Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Drusilla L. Burns, Charles R. Manclark
-
Patent number: 4831120Abstract: An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor C.sub.I renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes in 5' to 3' order the following: a DNA sequence which contains the promoter and operator P.sub.L O.sub.Type: GrantFiled: July 3, 1985Date of Patent: May 16, 1989Assignee: Bio-Technology General Corp.Inventors: Haim Aviv, Marian Gorecki, Avigdor Levanon, Amos Oppenheim, Tikva Vogel, Elisha Zeelon, Menachem Zeevi
-
Patent number: 4831121Abstract: Polydisperse native Pseudomonas flagellar (H) antigens (FAg) and methods of producing them are described, wherein each monomeric component contains certain amino acids, has a certain N-terminal amino acid sequence and a certain molecular weight and is free from pyrogenic substances. The ratio of the individual amino acids in the flagellar antigen of the individual H-serotypes is stated.For producing the polydisperse native Pseudomonas flagellar (H) antigens (FAg) methods are indicated, wherein Pseudomonas aeruginosa bacterial cultures or fractions thereof are treated with a detergent and the flagellar antigens are separated from the cultures. Prior to treatment or in the presence of the detergent, the bacterial culture is subjected to a shearing procedure, i.e. exposed to shearing forces. Thereafter, the flagellar antigens separated from the bacterial mass are isolated by a chromatographic treatment.Type: GrantFiled: October 2, 1986Date of Patent: May 16, 1989Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische ProdukteInventors: Thomas C. Montie, Friedrich Dorner, James L. McDonel, Artur Mitterer
-
Patent number: 4812441Abstract: A hypocholesterolemically active protein capable of reducing the blood cholesterol in mammals having the following characteristics:(a) Molecular weight by gel filtration: 30,000.+-.7,000(b) Isoelectric point: 7.9.+-.0.2(c) Amino acid composition (mole %):______________________________________ Glycine 25.23 Alanine 10.98 Glutamate 10.34 Asparaginate 8.20 Lysine 6.39 Leucine 5.58 Valine 5.41 Isoleucine 5.18 Threonine 4.23 Tyrosine 4.19 Serine 3.46 Proline 2.62 Arginine 2.60 Phenylalanine 2.51 Methionine 1.56 Histidine 1.30 Cysteine 0.16 ______________________________________(d) Pattern of electrophoresis: a sharp band on the anode side on polyacrylamide gel electrophoresis. This hypocholesterolemically active protein is derived from a microorganism belonging to the genus Streptococcus.Type: GrantFiled: February 7, 1986Date of Patent: March 14, 1989Assignee: Kabushiki Kaisya Advance Kaihatsu KenkyujoInventors: Yasuo Kawai, Kazunaga Yazawa
-
Patent number: 4801690Abstract: A lectin derived from the pili of piliated organisms, said lectin being non-covalently bindable to the pilus rod protein of said pili and separable therefrom by the action of aqueous sodium dodecyl sulfate, possessing a single binding site for binding to mammalian erythrocyte ghosts.Type: GrantFiled: March 24, 1986Date of Patent: January 31, 1989Assignee: Bactex, Inc.Inventors: Charles C. Brinton, Jr., Mark Hanson
-
Patent number: 4795803Abstract: An antigen which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunogenically active form, antibodies against which determinant react with the adhesion polypeptide produced by pathogenic adhesin-forming bacteria which adhere to mammalian tissue, antibodies against such antigen, and DNA expressing, as a principal gene product thereof, such antigen.Type: GrantFiled: February 19, 1986Date of Patent: January 3, 1989Assignee: Syn-Tek ABInventors: Frederick C. Lindberg, Bjorn O. Lund, Britt M. Baga, Mari E. Norgren, Mikael Goransson, Bernt E. Uhlin, Jan S. Normark, David L. Lark
-
Patent number: 4795805Abstract: Recombinant plasmids are constructed by inserting a DNA fragment coding for a fused protein of an adult T cell leukemia virus antigen peptide and an enzyme into a vector DNA. Microorganisms are transformed with the recombinant plasmid and thereafter cultured to express the fused protein. The fused protein is useful for the detection and diagnosis of adult T cell leukemia.Type: GrantFiled: October 2, 1987Date of Patent: January 3, 1989Assignees: Kyowa Hakko Kogyo Co., Ltd., Juridical Foundation, Japanese Foundation for Cancer ResearchInventors: Seiga Itoh, Susumu Sekine, Tadatsugu Taniguchi, Mitsuaki Yoshida, Haruo Sugano
-
Patent number: 4784589Abstract: A process is provided for the production of lymphocytosis promoting factor (LPF), filamentous haemagglutinin (FHA) and at least one fimbrial agglutinogen from a liquid culture of Bordetella pertussis, which comprises the steps of (a) separating the culture into cellular and supernatant fractions, (b) concentrating the supernatant fraction, (c) fractionating the concentrated supernatant fraction to isolate LPF and FHA containing fractions, and (d) isolating at least one fimbrial agglutinogen from the cellular fraction. A vaccine composition may be produced by mixing so-produced LPF, FHA and fimbrial agglutinogens produced.Type: GrantFiled: January 20, 1987Date of Patent: November 15, 1988Assignee: Public Health Laboratory Service BoardInventors: Andrew Robinson, Laurence I. Irons
-
Patent number: 4777241Abstract: A proteinaceous substance having the following biochemical characteristics:(A) a strong cytolytic activity against mouse tumor cells L-929, but not cytotoxic activity for normal cells such as human fetus fibroblasts, human adult skin fibroblasts and chinese hamster fibroblasts (Don, V-79) and therefore a high tumor specificity: and(B) a strong anti-tumor and immunogenic activity against Meth-A sarcoma. When said substance is injected intravenously to the syngenic BALB/C mice inoculated with Meth-A sarcoma at a quantity of more than 72 units head, not only hemorrhagic necrosis, but also complete degradation is observed. Thereafter, even if it is attempted again to transplant the Meth-A sarcoma cells under the skin of Mice cured completely, successful plantation is not observed because of an acquired immunity:(C) the substance has no pyrogenetic action after intravenous injection to rabbits:(D) a molecular weight of 45,000.+-.Type: GrantFiled: July 21, 1986Date of Patent: October 11, 1988Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Tsutomu Irikura, Koichi Takagi, Jiro Hosomi, Satoshi Murayama, Koji Saito, Takashi Okazaki
-
Patent number: 4772584Abstract: Polypeptides are disclosed which inhibit the binding of the C5a chemotaxin to polymorphonuclear leukocytes by cleaving a six amino acid peptide from the carboxy-terminus of the C5a chemotaxin. The polypeptides can be isolated from virulent strains of group A streptococci, s. pyogenes, by enzymatic or detergent extraction.Type: GrantFiled: May 23, 1986Date of Patent: September 20, 1988Inventors: Paul P. Cleary, Daniel E. Wexler
-
Patent number: 4766203Abstract: The present invention provides a new strain of micro-organism, Bacillus thuringiensis of pathotype C, a process for obtaining a toxin therefrom and an insecticide for combating Coleoptera containing the new micro-organism or a toxin obtained therefrom.Type: GrantFiled: March 13, 1987Date of Patent: August 23, 1988Assignee: Boehringer Mannheim GmbHInventors: Aloisius Krieg, Alois M. Huger, Wolfgang Schnetter
-
Patent number: 4766224Abstract: Purification and solubilization of proteins produced in transformant microorganisms as insoluble, biologically inactive inclusion bodies is effected by solubilizing the inclusion bodies in SDS; treating the SDS-protein solution with urea; removing the SDS and purifying the protein by chromatography on an anion-exchange resin having cationic groups attached to a polysaccharide support; and dialyzing the solution obtained from the anion-exchange resin to remove urea, thereby allowing the protein to fold into its native conformation. The solution thus obtained can be activated by removing soluble protein aggregates via ultrafiltration or chromatography on a weak anion-exchange column.Type: GrantFiled: August 19, 1985Date of Patent: August 23, 1988Assignee: International Minerals & Chemical Corp.Inventor: Steven K. Rausch
-
Patent number: 4764593Abstract: Disclosed are DNA sequences comprising structural genes coding for (1) a polypeptide having the amino acid sequence and properties of urogastrone and for (2) polypeptide analogs thereof which differ in terms of the identity and/or location of one or more amino acids, e.g., [Asp.sup.25 ] and Pro.sup.52, Pro.sup.53 ] analogs of urogastrone. Structural gene sequences may be provided with initial and terminal sequences which facilitate production of discrete protein products by selected host microorganisms as well as for expression by host organisms of fusion proteins, e.g., .beta.-lactamase-urogastrone and .beta.-galactosidase-urogastrone from which the desired products may be isolated.Type: GrantFiled: May 7, 1985Date of Patent: August 16, 1988Assignee: Amgen Inc.Inventors: Allen R. Banks, David L. Hare
-
Patent number: 4758507Abstract: Polypeptides displaying the antigenicity of hepatitis B virus e antigens, DNA sequences coding for those polypeptides, antibodies to those polypeptides and methods of producing and using those polypeptides, antibodies and DNA sequences. The polypeptides and antibodies of this invention are characterized by their use in compositions and methods for detecting hepatitis B virus infective carriers and in evaluating the course of HBV-related active liver disease.Type: GrantFiled: October 4, 1985Date of Patent: July 19, 1988Assignee: Biogen N.P.Inventors: Kenneth Murray, Patricia MacKay